^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    etentamig intravenous (ABBV-383 IV)

    i
    Other names: ABBV-383 IV, TNB-383B, TNB 383B
    Associations

    News

    Trials
    Company:
    AbbVie
    Drug class:
    CD3 agonist, BCMA inhibitor
    Related drugs:
    Associations

    News

    Trials
    10d
    M22-574: A Phase 3 study of Etentamig vs Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (3L+ RRMM Monotherapy Study) (2023-506668-15-00)
    P2/3, N=147, Active, not recruiting, AbbVie Deutschland GmbH & Co. KG | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    bortezomib • Xpovio (selinexor) • carfilzomib • dexamethasone • pomalidomide • Empliciti (elotuzumab) • etentamig intravenous (ABBV-383 IV)
    13d
    M25-586: A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (2025-520897-21-00)
    P2/3, N=24, Not yet recruiting, AbbVie Deutschland GmbH & Co. KG
    New P2/3 trial • Adverse events
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • etentamig intravenous (ABBV-383 IV)
    15d
    ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia (clinicaltrials.gov)
    P1/2, N=38, Not yet recruiting, Mayo Clinic
    New P1/2 trial
    |
    etentamig intravenous (ABBV-383 IV)
    1m
    A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (clinicaltrials.gov)
    P2/3, N=660, Recruiting, AbbVie | Trial primary completion date: Oct 2041 --> Jan 2042
    Trial primary completion date • Adverse events
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • etentamig intravenous (ABBV-383 IV)
    1m
    A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (clinicaltrials.gov)
    P2/3, N=660, Recruiting, AbbVie | Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2042 --> Oct 2041
    Enrollment open • Trial primary completion date • Adverse events
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • etentamig intravenous (ABBV-383 IV)
    3ms
    A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=283, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    clonoSEQ
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • pomalidomide • etentamig intravenous (ABBV-383 IV)
    3ms
    A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion (clinicaltrials.gov)
    P1/2, N=76, Recruiting, AbbVie | Trial completion date: Feb 2028 --> Sep 2031 | Trial primary completion date: Oct 2026 --> Sep 2031
    Trial completion date • Trial primary completion date • Adverse events
    |
    etentamig intravenous (ABBV-383 IV)
    4ms
    A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=180, Recruiting, AbbVie | Trial completion date: Mar 2027 --> Aug 2029 | Trial primary completion date: Mar 2027 --> Aug 2029
    Trial completion date • Trial primary completion date • Adverse events
    |
    etentamig intravenous (ABBV-383 IV)
    4ms
    A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion (clinicaltrials.gov)
    P1/2, N=76, Recruiting, AbbVie | Trial primary completion date: Dec 2025 --> Oct 2026
    Trial primary completion date • Adverse events
    |
    etentamig intravenous (ABBV-383 IV)
    6ms
    Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=135, Recruiting, AbbVie | Trial completion date: Jan 2037 --> Mar 2036
    Trial completion date • Adverse events
    |
    iberdomide (CC-220) • etentamig intravenous (ABBV-383 IV)
    6ms
    Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=135, Recruiting, TeneoOne Inc. | Trial primary completion date: Jun 2036 --> Mar 2036
    Trial primary completion date • Adverse events
    |
    iberdomide (CC-220) • etentamig intravenous (ABBV-383 IV)
    7ms
    A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan (clinicaltrials.gov)
    P1, N=8, Active, not recruiting, AbbVie | Trial primary completion date: Sep 2025 --> Mar 2026
    Trial primary completion date • Adverse events
    |
    etentamig intravenous (ABBV-383 IV)